文献速递妇产影像US

早孕期联合筛查后产前诊断检测与非典型染色体异常:对非侵入性产前检测 contingent 模型的意义

Prenatal diagnostic testing and atypical chromosome abnormalities following combined first-trimester screening: implications for contingent models of non-invasive prenatal testing.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-01-01

基于澳大利亚维多利亚州全州数据的回顾性队列研究显示,2014-2015年100418例联合早孕期筛查(CFTS)结果中非典型染色体异常总患病率为0.10%,在CFTS T21风险>1/10者中最高(4.6%),PAPP-A<0.2 MoM者中为6.9%,β-hCG<0.2 MoM者中为5.2%;55%的非典型异常发生于CFTS T21风险<1/300的孕妇,最常在超声检查中发现(47.1%)。作者认为,若对CFTS T21风险>1/100、血清PAPP-A或β-hCG<0.2 MoM或超声发现异常者提供侵入性诊断检测,可减轻在CFTS高风险后提供NIPT时对漏诊非典型染色体异常的担忧。

要点

  • CFTS T21风险>1/10者非典型染色体异常患病率4.6%,PAPP-A<0.2 MoM者6.9%,β-hCG<0.2 MoM者5.2%。
  • 55%的非典型异常发生于CFTS T21风险<1/300的孕妇,最常在超声检查中发现(47.1%)。
  • PAPP-A<0.2 MoM者中49.2%的CFTS T21风险低于1/100。

核心结论

  • 对CFTS T21风险>1/100、血清PAPP-A或β-hCG<0.2 MoM或超声发现异常者提供侵入性诊断检测,可减轻在CFTS高风险后提供NIPT时对漏诊非典型染色体异常的担忧,对筛查的contingent模型有启示。

研究设计与样本

  • 回顾性队列研究,使用澳大利亚维多利亚州全州产前数据集,2014-2015年队列共100418例CFTS结果(对应146776例活产,占68.4%),并与2002-2004年历史队列比较。

诊断标准与关键数值

  • 非典型染色体异常在整个CFTS队列中总患病率为0.10%;CFTS T21风险>1/10者中为4.6%;PAPP-A<0.2 MoM者中为6.9%;β-hCG<0.2 MoM者中为5.2%。

临床应用与阅片要点

  • 作者认为,对CFTS T21风险>1/100、血清PAPP-A或β-hCG<0.2 MoM或超声发现异常者提供侵入性诊断检测,可减轻对漏诊非典型染色体异常的担忧。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate by means of a population-based analysis of a cohort of women who underwent combined first-trimester screening (CFTS), changes in uptake of invasive prenatal diagnosis according to risk of trisomy 21 (T21) on CFTS, and prevalence and methods for ascertainment of atypical chromosome abnormalities.

METHODS: This was a retrospective cohort study using state-wide prenatal datasets from Victoria, Australia. A three-step approach was taken to analyze the data: (1) linkage of records between serum screening and diagnostic results; (2) comparison of rates of diagnostic testing according to CFTS T21 risk result category in a 2014-2015 cohort with those of a historical 2002-2004 cohort; (3) detailed analysis of atypical abnormalities in the 2014-2015 group according to CFTS T21 risk result, individual serum analyte level and other indications for invasive diagnostic testing.

RESULTS: In 2014-2015, there were 100 418 CFTS results issued for 146 776 births (68.4%). The overall prevalence of atypical chromosome abnormalities in the entire CFTS cohort was 0.10% and was highest in those with CFTS T21 risk > 1 in 10 (4.6%), or serum analyte levels < 0.2 multiples of the median (MoM) (6.9% for pregnancy-associated plasma protein-A (PAPP-A) and 5.2% for beta-human chorionic gonadotropin (β-hCG)). Almost half (49.2%) of women with PAPP-A < 0.2 MoM had a risk for T21 on CFTS of less than 1 in 100. The majority (55%) of atypical abnormalities occurred in women with CFTS T21 risk below 1 in 300, and were most commonly detected on ultrasound examination (47.1%).

CONCLUSION: Concerns regarding missed diagnoses of atypical chromosome abnormalities when non-invasive prenatal testing is offered after a result of high risk on CFTS can be mitigated if invasive diagnostic testing is offered to those women with CFTS T21 risk of > 1 in 100, serum PAPP-A or β-hCG < 0.2 MoM, or ultrasound-detected abnormality. This has implications for contingent models of screening. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Lindquist A, Poulton A, Halliday J, et al. Prenatal diagnostic testing and atypical chromosome abnormalities following combined first-trimester screening: implications for contingent models of non-invasive prenatal testing. Ultrasound Obstet Gynecol. 2018. PMID: 29226487. doi:10.1002/uog.18979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。